TRex Bio, Inc.
TRXB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002139097
In the last 90 days, TRex Bio, Inc. insiders filed 2 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysLast 90 days, $3.80M in total
- 2
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TRXB, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TRXB at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by TRex Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 15, 2026 (view filing)4:33 PM ET | Oct 13 | 2 days | Alexandria Venture Investments, LLC10% Owner | PPurchase | +178.6K | $14.00 | +$2.50M | +15.3%1.35M after | |
| Oct 13, 2026 (view filing)4:30 PM ET | Oct 8 | 5 days | SV Life Sciences Fund VI, L.P. and 2 others10% Owner | PPurchase | +92.9K | $14.00 | +$1.30M | New position7.36K after | 2 lots |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in TRex Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding TRXB in 13F filings for Q2 2026.
Holders of 5% or more of TRXB
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of TRex Bio, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 13D | 19.90%5.48M shares | New | Oct 16, 20261 filing | Oct 16, 2026 | SEC |
| Pfizer Inc | 13G | 7.20%1.97M shares | New | Oct 16, 20261 filing | Oct 16, 2026 | SEC |
| SV Biotech Crossover Opportunities Fund LP | 13D | 7.00%1.92M shares | New | Oct 16, 20261 filing | Oct 16, 2026 | SEC |
| Johnson & Johnson Innovation - JJDC, Inc. | 13G | 5.30%1.48M shares | New | Oct 15, 20261 filing | Oct 15, 2026 | SEC |